FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:1179-1181 September 14, 2006 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: We are investigating the safety and efficacy of patient-specific vaccines derived from short-term autologous tumor-cell lines in the treatment of melanoma.¹ In our current trial, patients with distant metastatic or recurrent regional melanoma are candidates for the receipt of an investigational vaccine consisting of autologous dendritic cells that have been incubated with irradiated autologous tumor cells from a proliferating cell culture and then suspended in granulocyte–macrophage colony-stimulating factor. The vaccine is administered subcutaneously once a week for 3 weeks, then monthly for 5 months.² Of the first 21 patients enrolled, 18 are alive a median of 3 . . . [Full Text of this Article]

This article has been cited by other articles:

• Yokoe, T., Tanaka, F., Mimori, K., Inoue, H., Ohmachi, T., Kusunoki, M., Mori, M. (2008). Efficient Identification of a Novel Cancer/Testis Antigen for Immunotherapy Using Three-Step Microarray Analysis. Cancer Res. 68: 1074-1082 [Abstract] [Full Text]  
• Costa, F. F., Le Blanc, K., Brodin, B. (2007). Concise Review: Cancer/Testis Antigens, Stem Cells, and Cancer. Stem Cells 25: 707-711 [Abstract] [Full Text]